On 10 June 2019, Luxembourg and the Netherlands were included into the mutual recognition agreementbetween the European Union (EU) and the United States Food and Drug Administration (FDA). The FDA thus confirmed the capability of these two additional EU Member States to carry out good manufacturing practice (GMP) inspections at a level equivalent to the United States (US). The agreement mutually recognises inspections of manufacturing sites for human medicines conducted in the different territories and this means that the FDA will now rely on a total of 26 Member States whose inspection results can replace their own inspections.
In June 2017, the European Commission confirmed that the FDA has the capability, capacity and procedures in place to carry out GMP inspections at a level equivalent to the EU. Since
1 November 2017, EU Member States and EMA can rely on inspection results from the FDA.
Actions for the agreement to be operational in all EU Member States are progressing. The planned date of operation is 15 July 2019. The mutual recognition agreement between EU and US regulators strengthens reliance on each other’s inspection expertise and resources. Mutual benefits for EU authorities and the FDA include:
- the ability to focus inspection resources on other parts of the world where active pharmaceutical ingredients and medicines for the EU or US markets are manufactured;
- prioritising inspections of medicines manufacturing sites for higher risk cases;
- reassuring patients that they can rely on the quality, safety and efficacy of all medicines, no matter where they have been manufactured;
- improving the ability to identify and address potential problems at manufacturing sites before they become a public health risk;
- reducing the administrative burden and costs from duplicative inspections for pharmaceutical manufacturers, including smaller producers…